CRBU trades 204.9% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CRBU achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Caribou Biosciences, Inc. (CRBU) has a Wall Street consensus price target of $5.00, based on estimates from 9 covering analysts. With the stock currently trading at $1.64, this represents a potential upside of +204.9%. The company has a market capitalization of $163M.
Analyst price targets range from a low of $3.00 to a high of $7.00, representing a 80% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CRBU trades at a trailing P/E of -1.0x. Analysts expect EPS to grow +16.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
EDITEditas Medicine, Inc. | $274M | $2.80 | $5.00 | +85.9% | Buy | — | 25 |
BEAMBeam Therapeutics Inc. | $3.7B | $35.53 | $48.00 | +40.6% | Buy | — | 27 |
NTLAIntellia Therapeutics, Inc. | $1.8B | $15.75 | $26.13 | +66.8% | Buy | — | 39 |
CRSPCRISPR Therapeutics AG | $5.2B | $54.36 | $71.67 | +32.5% | Buy | — | 38 |
FATEFate Therapeutics, Inc. | $251M | $2.15 | $5.50 | +163.2% | Buy | — | 31 |
ALLOAllogene Therapeutics, Inc. | $512M | $2.10 | $6.43 | +221.5% | Buy | — | 30 |
ILMNIllumina, Inc. | $24.5B | $161.38 | $151.40 | -6.5% | Buy | 31.0x | 50 |
TMOThermo Fisher Scientific Inc. | $172.4B | $464.01 | $599.70 | +29.1% | Buy | 18.7x | 42 |
PACBPacific Biosciences of California, Inc. | $410M | $1.32 | $1.00 | -28.6% | Buy | — | 18 |
TWSTTwist Bioscience Corporation | $5.3B | $85.01 | $75.00 | -14.3% | Buy | — | 13 |
Quick answers to the most common questions about buying CRBU stock.
The consensus Wall Street price target for CRBU is $5, representing 204.9% upside from the current price of $1.64. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CRBU has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $5 implies 204.9% upside from current levels.
CRBU's current price is $1.64 with a consensus target of $5 (204.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $7 for CRBU, while the most conservative target is $3. The consensus of $5 represents the median expectation. These targets typically reflect 12-month expectations.
CRBU is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CRBU stock forecast based on 9 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $3 (bear case) to $7 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CRBU, with a "Buy" consensus rating and $5 price target (204.9% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CRBU analyst price targets range from $3 to $7, a 80% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.